102940

KLS is a manufacturer of outdoor fitness equipment and a producer of pharmaceutical active ingredients and specialty chemicals. In its Chemical segment, the company manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates for generic and original drugs, primarily serving the Japanese market. It also produces antimicrobial agents, including pyridinone-based products under the brand name CleanBio, for use in personal care and marine antifouling coatings. Key customers in this segment include multinational corporations such as Unilever, Procter & Gamble, and Henkel, as well as Japanese pharmaceutical firms. In its Bio segment, KLS engages in the research and development of cell and gene therapies, with a pipeline including TG-C for osteoarthritis, KLS-2031 for neuropathic pain, and KLS-3021, a oncolytic virus. The company provides contract development and manufacturing organization (CDMO) services and has entered into technology transfer agreements for its bio-products. In its Sports Equipment segment, KLS produces and sells outdoor fitness facilities, including high-end, multi-function, and modern stainless steel series, as well as walking mats, primarily for the domestic Korean market.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Specialty Chemicals Homepage kls.kr
Sector Basic Materials IR page —
Tags
active pharmaceutical ingredients, antimicrobial agents, cell and gene therapy, cdmo services, outdoor fitness equipment, marine coatings, personal care ingredients, phosphoramidite, CleanBio, TG-C, KLS-2031, KLS-3021, Inbosakeju, BM102, Juniper Biologics, Pine Pharmaceuticals, Kolon Life Science
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 6.8%
ROI 4.3%
ROIC 2.9%
Profit margin 11.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 127.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 36.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 208.982B 161.387B 124.639B 161.584B 132.267B 129.413B 148.541B 132.68B 118.102B 158.284B 121.175B 130.633B 139.611B
Net profit 24.96B -93.086B -30.726B 2.133B -1.375B -43.195B -92.323B -50.69B -1.404B 12.665B 800.139M 5.855B 17.228B
Free cash flow -28.055B -22.279B -35.009B -27.159B -20.6B -10.05B — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 21.5B 21.7B 24.5B 29.5B 34.9B 20.3B 29.8B 26.1B 38.5B 37.7B
↳ YoY growth +24.3% +1.0% +13.1% +20.1% +18.6% -41.9% +46.6% -12.4% +47.8% -2.1%
↳ 5y CAGR +2.0% +10.3% +15.1% -1.1% +6.5% +1.2% +5.5% +1.5%
Borrowings, current (KRW) 28.9B 38.6B 40.5B 60.3B 67.1B 59.1B 73.5B 97.3B 116B 97.2B
Borrowings, non-current (KRW) 18.6B 10.4B 24.6B 18.1B 9.33B — — 9.98B 8.7B 4.99B
Bonds payable (KRW) — — — — — — 0.00 0.00 9.99B 7.82B
Lease liabilities (KRW) — 0.00 0.00 376M 611M 527M 455M 620M 2.02B 1.59B
Cash and deposits (KRW) 138B 55.8B 32.7B 5.91B 15B 27.8B 6.37B 7.56B 12.5B 10.6B
Intangible assets (KRW) 11.8B 17.1B 8.43B 900M 722M 1.72B 343M 333M 599M 1.03B
Right-of-use assets (KRW) — 0.00 0.00 361M 594M 513M 459M 639M 2.08B 1.59B
Net debt (borrowings + leases - cash) (KRW) -90.2B -6.78B 32.4B 72.8B 62B 31.8B 67.5B 90.3B 105B 93.1B
Cash flow detail
Operating cash flow (KRW) 28.1B -8.29B -13.6B -20.2B -7.31B -16.2B -20.9B -24.9B -14.1B 10.2B
Purchases of property, plant and equipment (KRW) — — -42.4B -30.8B -2.74B -4.41B -6.31B -10.1B -8.19B -38.3B
Purchases of intangible assets (KRW) -1.62B -605M -2.83B -5.78M 0.00 -43M -2.2M -93.3M -532M -124M
Change in receivables (cash effect) (KRW) -3.85B — — — — 3.25B -10.5B 4.21B — —
Change in inventories (cash effect) (KRW) 656M -11.6B -2.92B -2.72B -3.55B -3.81B -23.8B -2.13B — —
Change in payables (cash effect) (KRW) 9.35B — — — — 2.17B 4.53B -5.57B — —
Dividends paid (cash effect) (KRW) -668M -1.52B 0.00 0.00 — — — — — —
Share buybacks (cash effect) (KRW) 0.00 0.00 -462M 0.00 0.00 — — — — —
Interest paid (cash effect) (KRW) -1.91B -1.51B -1.64B -2.4B -2.04B -2.46B -2.99B -5.12B -7.44B -6.63B
Income taxes paid (cash effect) (KRW) -2.86B -377M 92.6M 124M 135,342 32.9M -818,530 -113M 6.78M -268M
Operating cash flow before change in receivables (KRW) 32B — — — — -19.4B -10.4B -29.1B — —
Free cash flow (OCF - PPE - intangibles) (KRW) — — -58.9B -51B -10.1B -20.6B -27.2B -35.1B -22.8B -28.2B
Income detail
Total comprehensive income (KRW) 11B 287B -98.8B -345B -43.1B -108M 67.9B -30.1B 2.77B 390B
Comprehensive income to owners (KRW) — — — — — — 67.9B -30.1B 2.77B 390B
Provision for credit losses (KRW) — 0.00 0.00 260M 116M 0.00 0.00 78M — —
Credit cost ratio (credit losses / average receivables) (%) — 0.0% 0.0% 1.0% 0.4% 0.0% 0.0% 0.3% — —
Reported Mar 31, 2017 Mar 30, 2020 Mar 17, 2021 Mar 17, 2021 Mar 17, 2021 Mar 21, 2024 Mar 18, 2025 Mar 18, 2026 May 15, 2025 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

News

분기보고서 (2026.09) Bull 0 Bear 0 Routine
[기재정정]반기보고서 (2026.06) Bull 0 Bear 0 Routine
반기보고서 (2026.06) Bull 0 Bear 0 Routine

Prompts

KLS (ticker 102940), listed in South Korea.

ETFs Holding KLS

ETF Weight in ETF Shares Market value As of
AVEE 0.00% 556 $ 4,815.34 Nov 16, 2026